Table II.
Univariate and multivariate analyses of clinical characteristics for progression-free survival of patients with advanced non-small-cell lung cancer.
| Univariate analysis | Multivariate analysis | |||||
|---|---|---|---|---|---|---|
| Variables | HR | 95% CI | P-value | HR | 95% CI | P-value |
| Age (<60/≥60 years) | 1.181 | 0.925–1.507 | 0.182 | 1.224 | 0.955–1.569 | 0.111 |
| Sex (Male/female) | 0.766 | 0.595–0.985 | 0.038 | 0.786 | 0.566–1.092 | 0.152 |
| Stage (III/IV) | 0.866 | 0.628–1.194 | 0.380 | 0.854 | 0.615–1.186 | 0.346 |
| Histological type (Adeno/sqcc) | 0.540 | 0.387–0.753 | 0.000 | 0.577 | 0.404–0.822 | 0.002 |
| Smoking history (None/yes) | 0.815 | 0.639–1.041 | 0.101 | 0.999 | 0.715–1.395 | 0.995 |
| ECOG PS (0+1/2) | 0.856 | 0.581–1.262 | 0.433 | 0.874 | 0.588–1.298 | 0.504 |
| Tumor location (Left/right) | 0.977 | 0.765–1.249 | 0.855 | 1.000 | 0.780–1.280 | 0.997 |
| NWR (≥0.67/<0.67) | 0.750 | 0.582–0.967 | 0.026 | 0.793 | 0.609–1.032 | 0.085 |
| NLR (≥2.85/<2.85) | 0.772 | 0.601–0.993 | 0.044 | 0.835 | 0.643–1.084 | 0.175 |
| PWR (≥37.23/<37.23) | 1.129 | 0.886–1.439 | 0.325 | 1.124 | 0.867–1.456 | 0.378 |
| PLR (≥166.56/<166.56) | 0.953 | 0.736–1.234 | 0.713 | 1.060 | 0.806–1.394 | 0.676 |
| MWR (≥0.074/<0.074) | 0.822 | 0.645–1.048 | 0.114 | 0.901 | 0.698–1.162 | 0.422 |
| MLR (≥0.31/<0.31) | 0.728 | 0.568–0.933 | 0.012 | 0.798 | 0.611–1.042 | 0.098 |
| LWR (≥0.24/<0.24) | 1.233 | 0.962–1.579 | 0.098 | 1.135 | 0.876–1.472 | 0.338 |
Adeno, adenocarcinoma; CI, confidence interval; ECOG PS, Eastern Cooperative Oncology Group performance score; HR, hazard ratio; LWR, lymphocyte/white blood cell ratio; MLR, monocyte/lymphocyte ratio; MWR, monocyte/white blood cell ratio; NLR, neutrophil/lymphocyte ratio; NWR, neutrophil/white blood cell ratio; PLR, platelet/lymphocyte ratio; PWR, platelet/white blood cell ratio; Sqcc, squamous cell carcinoma.